What SEC filings does Syndax Pharmaceuticals, Inc. submit to the SEC?

Syndax Pharmaceuticals, Inc. (SNDX) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about SNDX?

A Form 4 for SNDX discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Syndax Pharmaceuticals, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for SNDX?

The 10-K is Syndax Pharmaceuticals, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all SNDX SEC filings directly on EDGAR?

You can view all historical Syndax Pharmaceuticals, Inc. filings on the SEC EDGAR company page for SNDX. Each filing card on this page links directly to the original SEC document.

How often does Syndax Pharmaceuticals, Inc. file with the SEC?

Syndax Pharmaceuticals, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling SNDX shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

SNDX SEC Filing News — Syndax Pharmaceuticals, Inc.

Latest SEC filings for Syndax Pharmaceuticals, Inc. (SNDX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-04.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a n…

Sector: Healthcare Industry: Biotechnology Market Cap: $1.2B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for SNDX currently lean bearish. Of the 20 filing records displayed, 5 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

SNDX Filing Activity Snapshot 2026-02-10 — 2026-08-04

Insider Transactions (Form 4)

0 buys vs 5 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.18M

Botwood Nicholas A.J. (Head of R&D, CMO) · 2026-06-12

65,515 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 5 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 5 filings in this group are Form 4s for Syndax Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 5 insider filings shown, the breakdown is 5 open-market sale. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×5: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-07-09

SNDX insider Metzger Michael A (Director, Chief Executive Officer) sold 32,375 shares (~$784.8K)

Metzger Michael A, listed as Director, Chief Executive Officer at Syndax Pharmaceuticals Inc, reported an open-market sale of 32,375 SNDX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	32,375	$6.38	$206.6K
`S`	Open-market sale	32,375	$24.24	$784.8K
`M`	Option exercise derivative · Stock Option (Right to buy)	32,375	—	—

Filing: Form 4 (Insider Transaction) Insider: Metzger Michael A (Director, Chief Executive Officer) Shares: 32,375 Est. Value: $784.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-12

SNDX insider Botwood Nicholas A.J. (Head of R&D, CMO) sold 65,515 shares (~$1.18M)

Botwood Nicholas A.J., listed as Head of R&D, CMO at Syndax Pharmaceuticals Inc, reported an open-market sale of 65,515 SNDX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	22,515	$13.82	$311.2K
`S`	Open-market sale	34,280	$18.00	$617.0K
`M`	Option exercise	31,235	$13.82	$431.7K
`S`	Open-market sale	31,235	$18.14	$566.6K
`M`	Option exercise derivative · Stock options (Right to buy)	22,515	—	—
`M`	Option exercise derivative · Stock options (Right to buy)	31,235	—	—

Filing: Form 4 (Insider Transaction) Insider: Botwood Nicholas A.J. (Head of R&D, CMO) Shares: 65,515 Est. Value: $1.18M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-02

SNDX insider Goldan Keith A. (Chief Financial Officer) sold 1,177 shares (~$22.4K)

Goldan Keith A., listed as Chief Financial Officer at Syndax Pharmaceuticals Inc, reported an open-market sale of 1,177 SNDX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,177	$18.99	$22.4K

Filing: Form 4 (Insider Transaction) Insider: Goldan Keith A. (Chief Financial Officer) Shares: 1,177 Est. Value: $22.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-02

SNDX insider Metzger Michael A (Director, Chief Executive Officer) sold 6,847 shares (~$130.0K)

Metzger Michael A, listed as Director, Chief Executive Officer at Syndax Pharmaceuticals Inc, reported an open-market sale of 6,847 SNDX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	6,847	$18.99	$130.0K

Filing: Form 4 (Insider Transaction) Insider: Metzger Michael A (Director, Chief Executive Officer) Shares: 6,847 Est. Value: $130.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-10

SNDX insider Metzger Michael A (Director, Chief Executive Officer) sold 17,159 shares (~$360.8K)

Metzger Michael A, listed as Director, Chief Executive Officer at Syndax Pharmaceuticals Inc, reported an open-market sale of 17,159 SNDX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	17,159	$21.03	$360.8K

Filing: Form 4 (Insider Transaction) Insider: Metzger Michael A (Director, Chief Executive Officer) Shares: 17,159 Est. Value: $360.8K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 5 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Syndax Pharmaceuticals, Inc. has 5 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-07-08

SNDX Form 144 filed for proposed insider sale by MICHAEL METZGER (32,375 shares) ~$752.4K

MICHAEL METZGER filed a Form 144 with the SEC indicating intent to sell SNDX (Syndax Pharmaceuticals Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: MICHAEL METZGER Shares: 32,375 Est. Value: $752.4K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-12

SNDX Form 144 filed for proposed insider sale by Botwood Nicholas A.J. (31,235 shares) ~$566.7K

Botwood Nicholas A.J. filed a Form 144 with the SEC indicating intent to sell SNDX (Syndax Pharmaceuticals Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Botwood Nicholas A.J. Shares: 31,235 Est. Value: $566.7K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-11

SNDX Form 144 filed for proposed insider sale by Botwood Nicholas A.J. (34,280 shares) ~$609.4K

Filing: Form 144 (Proposed Sale Notice) Insider: Botwood Nicholas A.J. Shares: 34,280 Est. Value: $609.4K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-01

SNDX Form 144 filed for proposed insider sale by Goldan Keith A. (1,177 shares) ~$22.4K

Goldan Keith A. filed a Form 144 with the SEC indicating intent to sell SNDX (Syndax Pharmaceuticals Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Goldan Keith A. Shares: 1,177 Est. Value: $22.4K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-01

SNDX Form 144 filed for proposed insider sale by Metzger Michael A (6,847 shares) ~$130.0K

Metzger Michael A filed a Form 144 with the SEC indicating intent to sell SNDX (Syndax Pharmaceuticals Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Metzger Michael A Shares: 6,847 Est. Value: $130.0K

View on SEC EDGAR → Open Filing Document →

Material Events 7 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 7 in this period for Syndax Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-04